Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

In this randomized, controlled trial involving women in South Africa and Uganda, twice-yearly subcutaneous lenacapavir was superior to daily oral emtricitabine–tenofovir disoproxil fumarate in preventing HIV infection.

​   The New England Journal of Medicine: Search Results in Infectious Disease